US 12,110,333 B2
Methods to manipulate alpha-fetoprotein (AFP)
Richard S. Blumberg, Waltham, MA (US); Kristi Baker, Edmonton (CA); Michal Pyzik, Cambridge, MA (US); and Amit Gandhi, Billerica, MA (US)
Assigned to THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
Filed by THE BRIGHAM AND WOMEN'S HOSPITAL, INC., Boston, MA (US)
Filed on Feb. 25, 2019, as Appl. No. 16/284,005.
Application 16/284,005 is a continuation of application No. 15/306,665, abandoned, previously published as PCT/US2015/026860, filed on Apr. 21, 2015.
Claims priority of provisional application 62/101,539, filed on Jan. 9, 2015.
Claims priority of provisional application 61/984,252, filed on Apr. 25, 2014.
Prior Publication US 2020/0010543 A1, Jan. 9, 2020
Int. Cl. A61K 39/395 (2006.01); A61K 45/06 (2006.01); C07K 16/28 (2006.01); C07K 16/44 (2006.01)
CPC C07K 16/283 (2013.01) [A61K 39/3955 (2013.01); A61K 45/06 (2013.01); C07K 16/44 (2013.01); C07K 2317/76 (2013.01); C07K 2317/77 (2013.01)] 19 Claims
 
1. A method to inhibit or reduce FcRn and alpha-fetoprotein (AFP) interactions in a disease or disorder associated with elevated AFP levels comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising an inhibitor of AFP-FcRn and a pharmaceutically acceptable carrier, wherein said inhibitor of AFP-FcRn inhibits binding between alpha-fetoprotein (AFP) and FcRn, wherein the inhibitor of AFP-FcRn inhibits or blocks the AFP binding site on FcRn, wherein the inhibitor of AFP-FcRn is an antibody or antigen-binding fragment thereof, wherein the inhibitor of AFP-FcRn is an anti-FcRn ADM31 antibody, and wherein the subject has or has been diagnosed with cancer.